MediWound (NASDAQ:MDWD) Upgraded to Sell by StockNews.com

StockNews.com upgraded shares of MediWound (NASDAQ:MDWD) to a sell rating in a report released on Monday.

Several other brokerages have also commented on MDWD. Maxim Group lifted their price objective on MediWound from $25.00 to $30.00 and gave the stock a buy rating in a report on Tuesday, July 16th. HC Wainwright restated a buy rating and set a $28.00 price target on shares of MediWound in a research note on Tuesday, July 16th.

MediWound Stock Up 3.1 %

MDWD traded up $0.50 during midday trading on Monday, hitting $16.85. 95,196 shares of the company traded hands, compared to its average volume of 110,267. The company’s 50-day moving average is $17.26 and its 200 day moving average is $16.02. The firm has a market capitalization of $156.44 million, a PE ratio of -12.21 and a beta of 0.81. MediWound has a 52 week low of $7.10 and a 52 week high of $24.00.

MediWound (NASDAQ:MDWD) last released its quarterly earnings data on Wednesday, May 29th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.01. MediWound had a negative net margin of 64.24% and a negative return on equity of 21.67%. The firm had revenue of $4.96 million during the quarter, compared to analysts’ expectations of $4.65 million. On average, sell-side analysts predict that MediWound will post -1.86 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers bought a new stake in MediWound during the 2nd quarter worth approximately $131,000. Bank of New York Mellon Corp purchased a new stake in MediWound in the 2nd quarter worth $342,000. Janney Montgomery Scott LLC bought a new stake in MediWound during the first quarter valued at about $427,000. Sargent Investment Group LLC lifted its position in shares of MediWound by 7.0% in the fourth quarter. Sargent Investment Group LLC now owns 109,194 shares of the biopharmaceutical company’s stock valued at $1,111,000 after acquiring an additional 7,125 shares in the last quarter. Finally, Silverberg Bernstein Capital Management LLC lifted its position in shares of MediWound by 7.8% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 85,184 shares of the biopharmaceutical company’s stock valued at $1,214,000 after acquiring an additional 6,200 shares in the last quarter. Institutional investors own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.